DIRECTORS’ DEALINGS

Martin Diggle, a nonexecutive director at Oxford BioMedica, on Monday sold 223,583 shares at £8.08 in the gene therapy firm days after it was promoted to the FTSE 250 index. The shares were held in his Vulpes investment vehicles, which still own 14 per cent of the Parkinson’s disease pioneer.